Share
Information on reimbursement
-
08 March 2012
Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"
We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.
-
06 March 2012
Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).
-
21 February 2012 | Updated 22 February 2012
-
21 February 2012 | Updated 22 February 2012
-
02 February 2012
-
25 January 2012
-
20 January 2012
-
17 January 2012
-
16 January 2012
-
13 January 2012
-
05 January 2012
-
05 January 2012
-
04 January 2012
-
03 January 2012
-
12 December 2011
-
15 November 2011
-
11 November 2011
-
04 November 2011
-
01 November 2011
-
21 October 2011
